Report: Seborrheic Dermatitis Market Poised for Expansion through 2032

The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight.

The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) for treating patients with seborrheic dermatitis aged 9 and older, which was the second international approval of the drug. The report said the expansion will be driven by increasing prevalence and awareness of the condition, and that multiple multi-stage seborrheic dermatitis product pipelines launched during that timeframe will also drive awareness and market dynamics.

Other key manufacturers in the space include Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Maruho Co., Ltd., Kamedis Lts, Amorepacitic Corporation, Novartis and Incyte Corporation.

Some key products listed for analysis in the report include:

• ARQ 154
• Omiganan
• K40a
• ASF1057
• Azelaic Acid 15% Gel
• ARQ-154
• SEBORRHEAMEDIS Face Cream
• PAC-14028
• K301
• Elidel
• Ruxolitinib